Data on Nearly 7,000 Cases Reported at International Conference in
China
A large scale study led by renowned osteoporosis researcher Dr. Jianhua
Wang and presented at the recent 6th
International Conference on Bone and Mineral Research in Hohhot, China
affirms the precision and accuracy of CompuMed Inc.’s
(www.compumed.net)
OsteoGram® system for
low cost osteoporosis screening.
Dr. Wang’s presentation titled “Study
on Measurement of Phalangeal Bone Density by Radiographic Absorptiometry”
presented extremely precise results when performing short-term repeated
tests with CompuMed’s OsteoGram®
system. In addition, the study outcome was highly correlated to China’s
popular osteoporosis normal database, confirming the high accuracy of
OsteoGram. Radiographic absorptiometry (RA) is a technique for bone mass
measurement from radiographs of peripheral sites, most commonly the hand
or heel.
“This was one of the largest and most
thorough studies ever performed to study the value of RA in measuring
bone mineral density,” said CompuMed CEO
Maurizio Vecchione. “The results further
affirm that the OsteoGram is an effective and efficient alternative to
costly DXA systems.”
The OsteoGram is a software-based bone density measurement system that
can be used with digital x-ray equipment, as well as with older
film-based machines. It provides a low-cost alternative to DXA bone
mineral density (BMD) screening systems, which require dedicated and
costly equipment, office space and staff. The OsteoGram's benefits in
terms of cost and efficiency can help facilitate more widespread
osteoporosis screening and treatment of at-risk patients.
Last July, CompuMed announced that the company had received approval
from China’s State Food and Drug
Administration (SFDA) to sell the OsteoGram system and therefore work
with Chinese OEMs to penetrate one of the world’s
largest and fastest growing markets for osteoporosis screening. The
disease is especially prevalent in China, where the traditional diet
lacks the calcium required to build strong bones. More than 125 million
postmenopausal women are at risk for osteoporosis in China, with an
estimated 100 million-plus already suffering from the disease in various
stages.
About CompuMed:
CompuMed, Inc. (OTCBB:CMPD) develops and markets products and services
that combine advanced imaging with medical informatics.
